Anthony Nguyen, MD
Hematology & Oncology · Henderson, NVNPI 1831317551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $159,495 of the $210,127 with a category attached, or 75.9%. 28 manufacturers reported payments, led by Beigene USA, Inc. at 49.6% of the total. Among hematology & oncology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $747.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$104K
- AstraZeneca$70K
- Daiichi Sankyo Inc.$12K
- Beone Medicines USA, Inc.$10K
- AbbVie$3K
- Secura Bio, Inc.$3K
- plus $8K from 22 others
Across 183 payments — averaging $4513.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$305K
- AstraZeneca$210K
- Seagen Inc.$116K
- Eli Lilly$81K
- Beigene, Ltd.$57K
- Pfizer$37K
- plus $19K from 1 others
What the payments were for
- Consulting fees$38,14818%
- Speaking & faculty fees$159,49576%
- Grants$3500%
- Travel & lodging$4,5462%
- Food & beverage$7,3363%
- Education$2520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 76 | $104,321 |
| AstraZeneca(2 entities) | 68 | $70,225 |
| Daiichi Sankyo Inc. | 49 | $11,958 |
| Beone Medicines USA, Inc. | 10 | $10,060 |
| AbbVie(2 entities) | 5 | $2,872 |
| Secura Bio, Inc. | 9 | $2,647 |
| E.r. Squibb & Sons, L.L.C. | 8 | $2,615 |
| Exelixis Inc. | 4 | $2,094 |
| Beigene, Ltd. | 2 | $975 |
| Adaptive Biotechnologies Corporation | 2 | $769 |
| Novartis | 9 | $302 |
| Amgen | 2 | $200 |
| Novocure GmbH | 1 | $200 |
| Pfizer | 9 | $137 |
| Lilly USA, LLC | 4 | $135 |
| Eisai Inc. | 1 | $115 |
| Comsort, Inc | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 4 | $93 |
| Johnson & Johnson | 2 | $54 |
| Gilead | 2 | $39 |
| Bristol Myers Squibb | 2 | $39 |
| Sobi, Inc | 1 | $37 |
| Array Biopharma Inc | 5 | $36 |
| Tempus AI, Inc | 1 | $26 |
| Incyte Corporation | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Sanofi | 1 | $18 |
| Mannkind Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$210,127 in reported general payments places this provider in the 95th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 77 | $1,119,071 |
| IbrancePalbociclib | 28 | $441,998 |
| PromactaEltrombopag Olamine | 25 | $370,454 |
| RevlimidLenalidomide | 18 | $328,176 |
| Lenalidomide | 17 | $252,386 |
| XospataGilteritinib Fumarate | 12 | $229,022 |
| XtandiEnzalutamide | 12 | $174,280 |
| NinlaroIxazomib Citrate | 11 | $142,999 |
| Everolimus | 11 | $133,941 |
| EliquisApixaban | 93 | $69,905 |
| XareltoRivaroxaban | 19 | $19,178 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $5,603 |
| Hydroxyurea | 52 | $1,301 |
| Anastrozole | 41 | $1,160 |
| ValacyclovirValacyclovir Hcl | 14 | $919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $104,321 | $1,119,07177 claims |
| PfizerIbrance, Eliquis | $137 | $511,903121 claims |
| Astellas Pharma US IncXospata, Xtandi | $20 | $403,30224 claims |
| NovartisPromacta | $302 | $370,45425 claims |
| Bristol Myers SquibbRevlimid | $39 | $328,17618 claims |
| Johnson & JohnsonXarelto | $54 | $19,17819 claims |
| Lilly USA, LLCOlanzapine | $135 | $19726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Henderson
- Russell GollardHenderson$105K
- Rupesh ParikhHenderson$67K
- Ramalingam RatnasabapathyHenderson$25K
- Stephani ChristensenHenderson$10K
- Resty TibayanHenderson$10K
- Nutan ParikhHenderson$10K
- Muhammad GhaniHenderson$9K
- Khoi DaoHenderson$8K
- Gilbert NyamuswaHenderson$4K
- Nicholas VogelzangLas Vegas$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.